全球微生物原料藥市場：按宿主、類型、最終用戶和地區分類

2026年全球微生物衍生原料藥市場規模估計為745億美元，預計2033年將達到1,188.5億美元。預計2026年至2033年，該市場將以6.9%的複合年成長率成長。

微生物活性藥物成分（API）是指利用細菌、真菌、酵母等多種微生物進行微生物發酵生產的治療性物質或活性藥物成分。微生物活性藥物成分主要分為兩類：低分子量活性藥物成分及高分子量活性藥物成分。低分子量活性藥物成分是分子量較小的治療性物質，通常透過化學合成生產。高分子量活性藥物成分通常被稱為生物製藥，是複雜的治療性物質，例如單株抗體、疫苗和血液因子，透過重組DNA技術或可控微生物發酵生產。

與低分子量活性藥物成分（API）相比，高分子量微生物來源的API具有諸多優勢。其高標靶特異性和低毒性使其在治療癌症和糖尿病等慢性疾病方面具有更佳療效。此外，利用活微生物生產高分子量微生物來源API的製程能夠靈活生產多種產品，以滿足個人化醫療的需求。

市場動態

全球微生物來源原料藥市場主要受學名藥和生物相似藥成本效益帶來的日益成長的需求驅動。此外，微生物發酵在反應特異性、生產率和產率方面優於化學合成，這促使製藥公司加大對微生物原料藥生產的投資。然而，微生物發酵設施的建設、聚合物微生物原料藥生產流程的開發和規模化都需要大量資金，而且這些製程複雜、資本密集，嚴格的監管流程也會帶來許多挑戰，這些因素預計將會抑制市場成長。

開發創新發酵技術以降低生產成本，為微生物來源原料藥生產商帶來了龐大的商機。此外，由於這些產品屬於生物來源製品，若生產過程中缺乏嚴格的品管，極易受到污染，且批次間差異較大。這導致高分子量微生物來源原料藥面臨更高的監管門檻和產品成本。

從區域來看，北美市場佔據主導地位，這主要得益於其高昂的醫療成本和良好的醫療服務可近性。然而，以中國和印度等國家為首的亞太地區預計將成為成長最快的市場。這一成長歸功於經濟成長、可支配收入的增加、醫療基礎設施的不斷完善以及對生物製藥需求的日益成長。

本研究的主要特點：

• 本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
• 此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
• 本研究根據以下參數介紹了全球微生物原料藥市場主要參與者的概況：公司概況、產品系列、主要亮點、財務表現和策略。
• 本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
• 這份「全球微生物原料藥市場報告」旨在為該行業的各種相關人員提供參考，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
• 相關人員可以透過全球微生物原料藥市場分析中使用的各種策略矩陣來簡化決策過程。

目錄

第1章：研究目標與前提條件

• 分析目的
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行摘要

第3章 關鍵產業洞察

• 市場動態
• 促進因素
• 抑制因子
• 機會
• 影響分析
• PEST分析
• 波特的分析
• 技術進步
• 併購和合作趨勢
• 近期產品核可上市
• 企業市場占有率分析

第4章 全球微生物原料藥市場：依宿主分類，2021-2033 年（十億美元）

• 哺乳動物（10億美元）
• 細菌（10億美元）
• 真菌（10億美元）

第5章 全球微生物原料藥市場：按類型分類，2021-2033 年（十億美元）

• 抗體（10億美元）
• 胜肽類（10億美元）
• 蛋白質（10億美元）
• 小分子化合物（10億美元）
• 疫苗（10億美元）

第6章 全球微生物原料藥市場：依生產地點分類，2021-2033 年（十億美元）

• 內部研發（10億美元）
• 外包（10億美元）

第7章 全球微生物原料藥市場：依最終用戶分類，2021-2033年

• 製藥公司（10億美元）
• 生物製藥公司（10億美元）
• 其他（10億美元）

第8章 全球微生物原料藥市場：依分子類型分類，2021-2033 年（十億美元）

• 創新產品（10億美元）
• 非專利（10億美元）

第9章 全球微生物原料藥市場：依地區分類，2021-2033年

• 按地區
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • ASEAN
  • 其他亞太國家
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 其他拉丁美洲國家
• 中東
  • GCC
  • 以色列
  • 其他中東國家
• 非洲
  • 北非
  • 中非
  • 南非

第10章 公司概況：微生物原料藥市場

• KOLON LIFE SCIENCE
  • 公司簡介
  • 產品和服務組合
  • 近期趨勢和最新信息
  • 戰略概覽
• Shandong Lukang Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Lonza
• Merck & Co., Inc.
• Topfond Pharmaceutical Co., Ltd.
• DSM
• CSPC Pharmaceutical Group Limited

第11章 參考文獻與調查方法

• 參考
• 調查方法

Global Microbial API Market is estimated to be valued at USD 74.50 Bn in 2026 and is expected to reach USD 118.85 Bn by 2033, growing at a compound annual growth rate (CAGR) of 6.9% from 2026 to 2033.

Microbial APIs refer to therapeutic substances or active pharmaceutical ingredients produced through microbial fermentation using various microorganisms such as bacteria, fungi, or yeast. There are mainly two types of microbial APIs: small molecule APIs and large molecule APIs. Small molecule APIs are low-molecular-weight therapeutic substances that are usually produced through chemical synthesis. Large molecule APIs, commonly known as biologics, are complex therapeutic substances like monoclonal antibodies, vaccines, blood factors, etc. that are produced by recombinant DNA technology or controlled microbial fermentation.

Large molecule microbial APIs have certain advantages over small molecule APIs. Due to their high target specificity and lower toxicity, they provide better treatment outcomes for chronic diseases like cancer, diabetes, etc. The manufacturing process of large molecule microbial APIs using living microbes also allows for flexible production of a wide range of product variants catering to personalized medicine.

Market Dynamics:

The global microbial API market is driven by the rising demand for generic and biosimilar drugs owing to cost efficiency. Moreover, microbial fermentation offers advantages over chemical synthesis in terms of reaction specificity, productivity, and yields, which is encouraging pharmaceutical manufacturers to increase investment in microbial API production. However, the high capital requirement for setting up microbial fermentation facilities, developing, and scaling up the manufacturing process of large molecule microbial APIs is complex and capital-intensive and stringent regulatory processes are some of the factors expected to restrain market growth.

The development of innovative fermentation technologies to decrease production costs presents lucrative opportunities for microbial API manufacturers. Additionally, being biological products, they are more prone to impurities and batch-to-batch inconsistencies if not manufactured under stringent quality controls. This raises regulatory hurdles and the cost of goods for large molecule microbial APIs.

Among regions, North America dominates the market due to high healthcare expenditures and better access to care. However, Asia Pacific is poised to be the fastest-growing market arena, led by countries like China and India. This growth can be attributed to growing economies, rising disposable incomes, expanding medical infrastructure, and increasing demand for biologics.

Key features of the study:

• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global microbial API market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Merck & Co., Inc., Topfond Pharmaceutical Co., Ltd., DSM, CSPC Pharmaceutical Group Limited., KOLON LIFE SCIENCE, Teva Pharmaceutical Industries Ltd., Lonza, Akums Lifesciences Ltd., AbbVie Inc., Xellia Pharmaceuticals, BASF, Dr. Reddy's Laboratories and Lupin
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global microbial API market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global microbial API market

Detailed Segmentation:

Global Microbial API Market

• By Host
• Mammalian
• Bacterial
• Fungal
• By Type
• Antibody
• Peptide
• Protein
• Small Molecule
• Vaccine
• By Site
• In-house
• Outsourced
• By End User
• Pharmaceutical Companies
• Biopharmaceutical Companies
• Others
• By Region
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
• Top companies in Global Microbial API Market:
• Merck & Co., Inc.
• Topfond Pharmaceutical Co., Ltd.
• DSM
• CSPC Pharmaceutical Group Limited.
• KOLON LIFE SCIENCE
• Teva Pharmaceutical Industries Ltd.
• Lonza
• Akums Lifesciences Ltd.
• AbbVie Inc.
• Xellia Pharmaceuticals
• BASF
• Reddy's Laboratories
• Lupin

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Top 3 Market Findings
  • Top 3 Market Opportunity

3. Key Industry Insights

• Market Dynamics
• Drivers
• Restraints
• Opportunities
• Impact Analysis
• Pest Analysis
• Porters Analysis
• Technological Advancement
• Merger, Acquisition and Collaboration Scenario
• Recent Product Approvals/Launches
• Company Market Share Analysis

4. Global Microbial API Market, By Host, 2021 - 2033 ( US$ Billion)

• Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
  • Segment Trends
• Mammalian, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Bacterial, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Fungal, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)

5. Global Microbial API Market, By Type, 2021 - 2033 ( US$ Billion)

• Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
  • Segment Trends
• Antibody, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Peptide, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Protein, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Small Molecule, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Vaccine, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)

6. Global Microbial API Market, By Site, 2021 - 2033 ( US$ Billion)

• Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
  • Segment Trends
• In-house, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Outsourced, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)

7. Global Microbial API Market, By End user, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
  • Segment Trends
• Pharmaceutical Companies, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Biopharmaceutical Companies, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Others, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)

8. Global Microbial API Market, By Molecule, 2021 - 2033 ( US$ Billion)

• Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
  • Segment Trends
• Innovative, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Generic, 2021 - 2033( US$ Billion)
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)

9. Global Microbial API Market, By Region, 2021 - 2033, (US$ Bn)

• Introduction
  • Market Share Analysis, 2021 - 2033, ( US$ Billion)
  • Segment Trends
• By Region
  • Introduction
  • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• North America
  • Introduction
  • Market Size and Forecast, By Host, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Type, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Site, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By End-use, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Molecule, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Country, 2021 - 2033, ( US$ Billion)
    • U.S.
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Canada
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Europe
  • Introduction
  • Market Size and Forecast, By Host, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Type, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Site, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By End-use, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Molecule, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Country, 2021 - 2033, ( US$ Billion)
    • U.K
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Germany
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • France
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Italy
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Spain
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Russia
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Rest of Europe
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Host, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Type, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Site, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By End-use, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Molecule, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Country, 2021 - 2033, ( US$ Billion)
    • China
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • India
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Japan
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Australia
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • South Korea
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • ASEAN
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Rest of Asia Pacific
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Latin America
  • Introduction
  • Market Size and Forecast, By Host, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Type, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Site, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By End-use, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Molecule, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Country, 2021 - 2033, ( US$ Billion)
    • Brazil
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Mexico
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Argentina
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Rest of Latin America
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Middle East
  • Introduction
  • Market Size and Forecast, By Host, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Type, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Site, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By End-use, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Molecule, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Country, 2021 - 2033, ( US$ Billion)
    • GCC
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Israel
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Rest of Middle East
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
• Africa
  • Introduction
  • Market Size and Forecast, By Host, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Type, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Site, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By End-use, 2021 - 2033, ( US$ Billion)
  • Market Size and Forecast, By Country, 2021 - 2033, ( US$ Billion)
    • North Africa
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • Central Africa
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)
    • South Africa
      • Introduction
      • Market Size and Forecast, 2021 - 2033, ( US$ Billion)

10. Company Profiles - Microbial API Market

• KOLON LIFE SCIENCE
  • Company Overview
  • Product/Service Portfolio
  • Financial Performance
  • Recent Developments/Updates
  • Strategic Overview
• Shandong Lukang Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• Lonza
• Merck & Co., Inc.
• Topfond Pharmaceutical Co., Ltd.
• DSM
• CSPC Pharmaceutical Group Limited

11. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact